Minimal Change Disease Relapse After Initial Glucocorticoid Therapy: Next-Step Management
This protocol is for patients with minimal change disease (MCD) who have experienced an infrequent relapse — fewer than three episodes per year — after receiving an initial course of high-dose oral glucocorticoids. It addresses the clinical decision point that arises when the first-line regimen did not sustain remission.
Previous Line — Why It Was Not Sufficient
The preceding treatment used high-dose oral glucocorticoids (prednisone or prednisolone). The target — complete remission of nephrotic syndrome — was achieved initially (approximately 50–75% of patients respond within 4–16 weeks), but remission was not maintained and the patient has now relapsed. This infrequent relapse is the trigger for the current protocol.
Clinical Goal
Return of proteinuria to a normal range, constituting remission of the relapse episode.
Treatment Approach — Partial Overview
Infrequent relapses of MCD can be managed with a further course of oral glucocorticoids, structured with a specific duration and tapering approach that differs from the initial high-dose induction — designed to limit cumulative exposure while targeting remission. The complete regimen, tapering schedule, and decision criteria are available in the full protocol.
References
DOI: 10.1038/kisup.2012.18
- Infrequent relapses may be treated with glucocorticoids without incurring major side effects if the duration of therapy is limited.
- One regimen is to administer oral prednisone at a daily dose of 1 mg/kg (maximum dose of 80 mg/d) for 4 weeks or until remission is achieved, followed by 5-mg decrements every 3–5 days to discontinuation within 1–2 months.
- In 1 study, patients were treated with 20–30 mg of prednisolone for a minimum of 7 days or additionally with cyclophosphamide until proteinuria returned to a normal range, suggesting that the high doses of glucocorticoids, as with the initial treatment of MCD, may not be needed.
View source ↗